1. XIMINO [prescribing information]. Scottsdale, AZ. Journey Medical Corporation; 2020.
2. Del Rosso JQ. Weight-based Dosing and Extended-release Formulation of Minocycline Tablets: Is There Clinical Significance? J Clin Aesthet Dermatol. 2009;2(1):44-7.
3. Fleischer AB, Dinehart S, Stough D, et al. Safety and Efficacy of a New Extended Release Formulation of Minocycline. Cutis. 2006;78(suppl 4):21-31.
4. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician. 2000;62(8):1823-1830.
5. Overgaard AB, Højsted J, Hansen R, et al. Patients' evaluation of shape, size and colour of solid dosage forms. Pharm World Sci. 2001;23(5):185-8.
6. Well D. Acne vulgaris: A review of causes and treatment options. Nurse Pract. 2013;38(10):22-31; quiz 32.
7. Cleveland Clinic. Acne. https://my.clevelandclinic.org/health/diseases/12233-acne. Accessed May 26, 2021.
8. Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17-32.
9. American Academy of Dermatology. Acne tips for managing. https://www.aad.org/public/diseases/acne-and-rosacea/acne. Accessed May 26, 2021.
10. US Dept of Health and Human Services. What is acne? http://www.niams.nih.gov/Health_Info/Acne/acne_ff.pdf. Updated November 2014. Accessed May 26, 2021.
11. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines for the care and management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-73.
XIMINO® is a registered trademark of Journey Medical Corporation.
JMC-XIM-071921 ©2023 Journey Medical Corporation. All rights reserved.
XIMINO (minocycline hydrochloride) is a tetracycline-class drug used to treat pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne vulgaris in people 12 years and older.
XIMINO is not effective for acne that is not red-looking (this means acne that is not inflammatory). It is not known whether XIMINO is: safe for use longer than 12 weeks, safe and effective for the treatment of infections, or safe and effective in children under the age of 12 years.
Do not take XIMINO if you are allergic to tetracycline class medicines. Ask your doctor or pharmacist for a list of these medicines if you are not sure.
Before you take XIMINO, tell your doctor if you have kidney or liver problems, diarrhea or watery stools, vision problems, plan to have surgery with general anesthesia, or have any other medical conditions.
You should not take XIMINO if you are a male, and you and your female partner are trying to conceive a baby.
You should not take XIMINO if you are pregnant or plan to become pregnant. XIMINO may harm your unborn baby. Taking XIMINO while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before taking XIMINO if you plan to become pregnant or if you are already taking XIMINO and plan to become pregnant. Stop taking XIMINO and call your doctor right away if you become pregnant while taking XIMINO.
You should not take XIMINO if you are breastfeeding or plan to breastfeed. XIMINO passes into your milk and may harm your baby. You and your doctor should decide if you will take XIMINO or breastfeed. You should not do both.
Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. XIMINO may affect the way other medicines work, and other medicines may affect how XIMINO works. Especially tell your doctor if you take birth control pills, blood thinner medicine, penicillin antibiotic medicine, antacids that contain aluminum, calcium, or magnesium, iron-containing products, or an acne medication that contains isotretinoin. XIMINO and penicillins should not be used together. XIMINO should not be taken with an acne medication that contains isotretinoin. XIMINO and isotretinoin should not be used together. Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.
The most common side effects of XIMINO were headache, tiredness, dizziness or spinning feeling and itching.
Call your doctor if you have a side effect that bothers you or that does not go away. Your doctor may do tests to check you for side effects during treatment with XIMINO.
These are not all the side effects with XIMINO. Ask your doctor or pharmacist for more information. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You are about to leave the XIMINO product website. Journey Medical does not administer the information on the linked website, and does not monitor or endorse the information. This link solely provides additional information that may help you locate and identify other Internet resources that may be of interest.
You are about to leave the XIMINO Patient information area. The information provided in the Physician area is intended for U.S. healthcare professionals. If you are not a healthcare professional, please ask your healthcare provider about XIMINO.
Patient Instructions
Present this card to your participating pharmacist, along with your insurance card, and a valid prescription for XIMINO® (minocycline hydrochloride) extended-release capsules. Commercially insured patients may receive savings to reduce the co-pay amount to $7. Cardholders with questions call 1-888-786-5876.
Eligibility Criteria
This offer is only good with a prescription of XIMINO. This Savings Card is valid for XIMINO 45mg (NCDs 10631-0330-30, 69489-0121-30), XIMINO 90mg (NDCs 10631-0331-30, 69489-0122-30), and XIMINO 135mg (NDCs 10631-0332-30, 69489-0123-30). This Savings Card is also valid for Minocycline Hydrochloride 45mg (NDC 72143-0221-30), Minocycline Hydrochloride 90mg (NDC 72143-0222-30), and Minocycline Hydrochloride 135mg (NDC 72143-0223-30). This offer is not valid for prescriptions reimbursed by Medicare, Medicaid, federal or state programs (including any state prescription drug programs). Offer good only in the United States and cannot be redeemed at government subsidized pharmacies. The selling, purchasing, trading, or counterfeiting of this offer is prohibited by law. Not valid with any other offer. Maximum reimbursement limits apply. Void where prohibited. Good for a maximum of 12 uses per card.
Pharmacist Instructions
This card must be accompanied by a valid prescription for XIMINO. Please submit the co-pay authorized by the patient's primary insurance as a secondary transaction to Opus Health. Pharmacists with questions, please call Opus Health at 1-800-364-4767.
This card is the property of Journey Medical Corporation and Opus Health and must be returned upon request. Not valid for patients covered under Medicare, Medicaid, or similar state or federal programs. Card is nontransferable. This card is not an insurance benefit. Both parties retain the right to rescind, revoke, amend, or terminate this offer of the program in its entirety at any time.
This savings card is also valid for Minocycline Hydrochloride 45mg (NDC 72143-0221-30), Minocycline Hydrochloride 90mg (NDC 72143-0222-30), and Minocycline Hydrochloride 135mg (NDC 72143-0223-30).
Studies 1 and 2, as shown, were both 12-week, multicenter, randomized, double-blind, placebo-controlled trials assessing the safety and efficacy of ER minocycline hydrochloride in the treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris. A combined total of 924 patients from the 2 studies (including treated patients plus placebo patients) ≥12 years of age with a mean age of 20 years were dosed by weight: 1mg/kg once daily. Primary endpoints were mean percent change in inflammatory lesion count from baseline to week 12 and percentage of subjects clear or almost clear on the Evaluator's Global Severity Assessment (EGSA) at week 12.4
Based on results of United States Pharmacopea (USP) dissolution studies comparing various IR minocycline 100mg formulations, a rapid rise in serum levels was observed within the first hour after dosing. At 15, 30, 45, and 60 minutes, 97%, 105%, 106% and 108%, respectively, of minocycline was released from the generic IR formulations. This rapid rise appears to correlate with an increase in vestibular events.2
The release of minocycline from the ER formulation tablets is slow, steady and prolonged. In this study, at 15, 30, 45 and 60 minutes, 14%, 26%, 32% and 43%, respectively, of minocycline was released from the ER formulation.2
In a phase 2, double-blind, randomized, 12-week trial (N=241) of ER minocycline tablets administered once daily in subjects aged 12 to 30 years with moderate to severe acne vulgaris, the incidence of acute vestibular adverse events (defined as dizziness, nausea, tinnitus, vertigo or vomiting noted within the first 5 days of treatment) appeared to be dose-related. The combined data from the phase 2 and phase 3 clinical trials showed that the percentage of subjects experiencing individual vestibular adverse reactions was comparable among those treated with ER minocycline 1mg/kg once daily (n=674) and placebo (n=364).4
Two 12-week, multicenter, randomized, placebo-controlled trials assessed the safety and efficacy of ER minocycline hydrochloride in the treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris. Patients ≥12 years of age (N=1038) with a mean age of 20 years were dosed by weight: 1 mg/kg once daily. Primary endpoints were mean percent change in inflammatory lesion count from baseline to week 12 and percentage of subjects clear or almost clear on the Evaluator's Global Severity Assessment (EGSA) at week 12. Pooled data from phase 2 and 3 studies, intent-to-treat population (N=1038), were used in the final adverse reactions table.4